Premium
Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian national cancer institute long‐term experience
Author(s) -
Ornellas Antonio Augusto,
Chin Eduardo Wei Kin,
Nóbrega Bernardo Lindenberg Braga,
Wisnescky Aristóteles,
Koifman Nelson,
Quirino Raul
Publication year - 2008
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20980
Subject(s) - medicine , lymphadenectomy , carcinoma , survival rate , stage (stratigraphy) , surgery , basal cell , metastasis , cancer , urology , paleontology , biology
Abstract Background and Objectives We reviewed our long‐term experience with surgical treatment of patients with penile carcinoma. Methods From 1960 to 2006, 688 patients with penile carcinoma underwent surgical treatment at our Institute. Several forms of surgical treatment were compared and follow‐up data analyzed. Results Stage stratification demonstrated a better survival rate for patients with stages T1N0 and T1N1,T2N0‐1. Patients with well differentiated carcinoma had a higher survival rate than those with moderately and poorly differentiated carcinoma ( P < 0.0001 and P = 0.006). Risk stratification showed a better survival rate for patients in the low‐risk group (T1G1,T1G2) ( P = 0.013 and P < 0.00001). Patients in the intermediate group (T2G1,T2G2,T3G1,T3G2) presented a higher survival rate than patients in the high‐risk group (T1‐3G3,T4G1‐3) ( P < 0.00001). Patients who underwent immediate lymphadenectomy had a better survival rate than those who underwent delayed lymphadenectomy ( P = 0.002). Conclusions Stage and tumor grade affected the prognosis of the disease. The presence and the extent of metastasis to the inguinal region were the most important prognostic factors for survival in our patients. Immediate lymphadenectomy is indicated in all patients. Since recurrences were noted within 8, 10, and 25 years after primary treatment, a frequent and lasting follow‐up is essential for all patients. J. Surg. Oncol. 2008;97:487–495. © 2008 Wiley‐Liss, Inc.